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ŵźĩźƸƃƾĪƃżěƭƺƬƗƵŚĮƄƳřŵ ŢſřƵŵƺŝ .  
ŵřƺƯ ƹ ƁƹŹ ŚƷ :ƾƠǀƇƺţƶƘƫŚƐƯĨƿŹŵ– ƾƬǀƬŰţÓÍ ŢƟŚƿŹŵƱƹŶŝƹƶƴǀſŵŹŵŚŝŹŚŝƲǀƫƹřƽřźŝƶĩƽŹŶƇƲƿĦƳōƶŝǈŤŞƯƱřŹŚưǀŝŻřźƠƳƷǀĢ ƶƳƺĭ ƾŞƬƣƽƹŹřŵ
ŹŵŜƬƣƆƈŴŤƯĨƃżěƶŝƵŚĮƳŚƯŹŵ ƱŚſōƁƹŹƶŝƵŵƺưƳƶƘūřźƯŵźĩźƸƃƾĪƃżěƭƺƬƗƵŚĮƄƳřŵƶŝƶŤƀŝřƹŜƬƣ ŶƳŶƃśŚŴŤƳř .ŻŹƹŢƀţŢŰţ řŶŤŝřŹřźƣƁ
řŵŚƳŚĩŜƬƣƲưŬƳřƶƯŚƴƄſźěƪǀưĪţŚŝžĜſŶƴŤƟźĭ ƾƴƿĦƳōƵƹźĭŚƿŽǈĩƱō ŚƷ ƁƹŹƶŝƹƆŴƄƯ śƹƞƫřƹŵŹŵƵŵŚſƾƟŵŚƈţ ŶƳŶƃƮǀƀƤţ .ƵŵŚƠŤſřŚŝŻř
ƶƯŚƴƄſźě ĨǀƟřźĭƺƯŵšŚƈŴƄƯĨƿĥƺƫƺƿżǀƟƽŚƷźǀƜŤƯŢŞŧƶĭźŝƹƾƟźƈƯƽƹŹřŵƕƺƳƹšŶƃŵřŶƘţ ƾŞƬƣŵŹŵšǈưů ƹ ƶŬǀŤƳŢŞŧƱřŹŚưǀŝƁŻŹƹŢƀţ
Ŷƿŵźĭ .ƱŚƯŹŵ źƷƶƳřŻƹŹŪƫŚƘƯĨƃżěƎſƺţŢƄƷ ŚŝŢƗŚſÏÍ ƾƬǀƯ ƭźĭ ƞƫřƵƹźĭƽřźŝƩƺƫƺƳřźěƹźě ƹÐÍ ƾƬǀƯ ƭźĭ śƵƹźĭƽřźŝƭŻŚǀŤƬƿŵ šŶƯƶŝ Ƃƃ ƶŤƠƷ 
Ŷƃƕƹźƃ .źƷ ƶŝƱřŹŚưǀŝƶŤƠƷƹŵƵŚĮƳŚƯŹŵ ůŵřŶƘţƹšŶƃźƔƳŻřƢƤŰƯƎſƺţřŶŤŝřƵŵƺưƳƶƘūřźƯƶƏƺŝźƯŵŹŵšǈưƾſŹźŝƾƿƹŹřŵƾŞƳŚūƉŹřƺƗžĜſƹ 
ƶƴƿŚƘƯŪƫŚƘƯĨƃżěƎſƺţƯƾ ŶƳŶƃ .ƱŚƯŹŵƵŹƹŵƭŚưţřŹŵƂƃ ŤƠƷ) ƶƁŻŹƹŢƀţŢŰţƵƹźĭƹŵƱřŹŚưǀŝƭŚưţľřŵŶŬƯ ŶƴŤƟźĭŹřźƣ .ƶƘƫŚƐƯƶŝŵƹŹƹƽŚƷŹŚǀƘƯ 
ƁŻŹƹŢƀţƱŶƃŢŞŨƯƹƽŹŶƇƲƿĦƳōĨǀĜǀţŵŹŵ ŚŝƱŚƯŹŵƶƘƫŚƐƯŻřũƹźųƽŚƷŹŚǀƘƯƹƾŞƬƣƽŚƷƹŹřŵźƿŚſƾƿƹŹřŵƉŹřƺƗŵƺūƹŢŝŚƿŵƶŝǈŤŝřƹƹŹřŵƖƐƣ
ŢſřƵŵƺŝƱŚŤſŹŚưǀŝŹŵƽźŤƀŝ .Ƶŵřŵ ŚƷ ŹřżƟřƭźƳŻřƵŵŚƠŤſřŚŝSPSS ƹŢƀţ ŚƷƽ ƿŵźĭƪǀƬŰţƹƶƿżŬţƾƬǀƬŰţƹƾƠǀƇƺţƽŹŚƯōŶ   
ƶŤƟŚƿ ŚƷ :ƱōźĮƳŚǀŝŪƿŚŤƳ ƕƺưŬƯŻřƶĩŵƺŝÓÍ ĭƹŵŹŵŹřŶƿŚěƲƿĦƳōŹŚưǀŝƭŻŚǀŤƬƿŵƹƩƺƳřźěřźěƵƹźÐ/ÓÕ ŶƇŹŵ ƹŵźƯÔ/ÐÎ ŶƇŹŵ ŵƺŝƱŻ .ƱřƹřźƟ źţƿƲ ŵŹŵŢǀƠǀĩ
ŚŝƞǀƠųŵŹŵƾƴƿĦƳōÒÍ ŶƇŹŵ ŚŝƵŵŻŢƄůƹŵŹŵƾƴƿĦƳōŵŹŵƲƿźŤưĩƹÎÍŶƇŹŵ ŵƺŝ .ƱřƹřźƟ źţƿƲ ŚŝƾƴƿĦƳōŽǈĩÕÍŶƇŹŵ ŽǈĩƶŝƍƺŝźƯÏ ƲƿźŤưĩƹ Ʊō
ŽǈĩƶŝƍƺŝźƯÐ ŚŝÐ/Õ ŶƇŹŵ ŢſřƵŵƺŝ .ŚŝũƹŻƾţƱƺƯŻōåê/åp< ƵŹƹŵƩƺƏźŝƱŚƯŹŵŻřƪŞƣŚŝƶƀƿŚƤƯŹŵƩƺƳřźěƹźěƶĩŵƺŝƱōźĮƳŚǀŝŧŐţŵŹŵǀź ƶŝƶŤƃřŵ
ŹƺƏƽ ƶĩ řƿƲ ŧŐţǀź ŢſřƵŵƺŝŵŹŵƵŹƹŵƩƺƏƹŵŹŵšǈưůŵřŶƘţźŝƭŻŚǀŤƬƿŵƵƹźĭŹŵ. ŚŝƪƤŤƀƯƾţƱƺƯŻōÍÒ/ÍP< šƹŚƠţźĮƳŚǀŝƾºƴƘƯ Źřŵ     źºŧřƲǀºŝƽŹŚºƯō
ƶŝƵŵƺŝŵŹŵšǈưůŵřŶƘţźŝƭŻŚǀŤƬƿŵƹƩƺƫƺƳřźěƹźěƵƹźĭƹŵŹŵƱŚƯŹŵƾƄŴŝŹƺƏƽ ƶĩ šǈưůŵřŶƘţƂƷŚĩźŝƭŻŚǀŤƬƿŵŧŐţŵŹŵǀź ƂŴŝźŧř źţ ŢſřƵŵƺŝ .ƱƺƯŻō
ŚŝźƄǀƟƢǀƣŵÍÒ/ÍP< ƝǈŤųřźĮƳŚǀŝƾƴƘƯ Źřŵ ŤƬƿŵƹƩřŹŶƴƿřƵƹźĭƹŵŹŵƁŻŹƹŢƀţƱŶƃƾƠƴƯƲǀŝƽŹŚƯōƶŝƵŵƺŝƭŻŚǀŹƺƏƽ ƶĩ ƱřŹŚưǀŝƭŻŚǀŤƬƿŵƵƹźĭŹŵƶŝ
ŹƺƏ ƾƴƘƯ Źřŵƽ ƁŻŹƹŢƀţƱō ŚƷ ŢſřƵŶƃƾƠƴƯ .  
ƶŬǀŤƳƹŦŰŝ ƽźǀĭ :ŵŹŵŢǀƠǀĩźŝƭŻŚǀŤƬƿŵƹƩřŹŶƴƿřƶģźĭŵŹŵšǈưůŵřŶƘţƵŵƺŝźŧƺƯŹřŶƿŚěƲƿĦƳōƽřŹřŵƱřŹŚưǀŝŵŹŵƵŹƹŵƩƺƏ .ŚƯřřºƿƲ ŧŐºţǀź   Ǝºſƺţ
ƭŻŚǀŤƬƿŵ ƂŴŝźŧř źţ ŢſřƵŵƺŝ .ŶǀŗŚţƶģźĭřƿƲ ŧŐţǀź ŵźǀĭŹřźƣƾſŹźŝŵŹƺƯŶƿŚŝźŤƄǀŝƮŬůŚŝ .  
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ƶƯŶƤƯ  
     ŢºƬƗƶºŝƱĦǀºƀĩřŻřŢºǀƯƹźŰƯƭƺƸƠƯƶŝŵŹŚĩƺǀƯƾưĪƀƿř
ŢºſřƾƳŚſŹƱƺųƂƷŚĩ .ŚºƃƿƖ źºţƿƲ     ŵŹŚºĩƺǀƯƾưĪºƀƿřŢºƬƗ
ĨǀţƹźƬĪſřƹźţŹřƽŹŚưǀŝ źƃƿƱŚ ŚƷƽ ) ŢſřźƳƹźĩƩŚƿŵŹŚĩƾěřæ( .
ƽřŹřŵƾŞƬƣƲƿĦƳōƭźƟ ŚƷƽ ŵŶƘŤƯƷŚĮƳŚƯŹŵƱƺģƾĨǀţƹźƬĪſřƹźţř
ƲƿĦºƳōƹĨǀŤſŚĜſřƹŻřƹ ŹřŶºƿŚěŚƳ      ĨǀţƹźƬĪºſřƹźţōƭźºƟƶºĩŢºſř
îåŶƇŹŵ ƪǀĪƄţřŹƲƿĦƳōŵŹřƺƯƯƾ ŶƷŵ )ç( .ŹřŶƿŚěƽŹŶƇƲƿĦƳō
ŻřƾĪƿšŹƺƇ ŚƷƽ   ƶºŝƱŚƯŹŵƶĩŢſřźƳƹźĩơƹźƗƽŹŚưǀŝźƷŚƔţ
   ƱōŻřƾºƃŚƳīźºƯƹŵŹŚĩƺǀƯŽƺŤĩŹŚƠƳřŻřŢſřƲĪưƯƱōƖƣƺƯ
) ŶƿŚưƳƽźǀĭƂǀěè( .ƮƸƯ źţƿƲ    ƽŹŚºưǀŝƲºƿřŹŵƾƳŚƯŹŵŢǀưƷř
ƾƳřƺţŚƳƂƿřżƟřŻřƽźǀĭƺƬūƽŹŶºƇƲƿĦņƳōŵŚůƶƬưůƱŵźĩƮĩ ƹ
ŽźƿŵƉŹřƺƗŻřƽźǀĭƺƬūŝǀŹŚưƽ ŚƷƽ ơƹźƗƹŜƬƣ Ţſř .ƱŚƯŹŵ
ƾƿƹŹřŵƾĭŶƳŻĨŞſƹƶƿŸƜţ ſŚſřƾ źţƿƲ   ŢºſřƱŚƯŹŵŌżū)é .(
ƝŶƷ Żř ƱŚƯŹŵ Ʋƿř ƽŹŚưǀŝ ƞƣƺţ Śƿ ƂƷŚƧ ƶƳŚƄƳ ŚƷƽ ŝǀŹŚºưƽ ƹ 
ŚƤţŹřƽ ŢǀƠǀƧ ƾĭŶƳŻ ŹŚưǀŝ ƶŝ ƵřźưƷ ƂƿřżºƟř ƩƺºƏ źºưƗ ƱƹŶºŝ 
ƶºƋŹŚƗ  ) Ţºſřê( .   ƽŹŶºƇƲƿĦºƳřƱŚºƯŹŵ     ƱŚºƴǀưƏřźºŝƪưŤºƄƯ
ŹŚưǀŝƶŝƱŶǀƄŴŝƵŶƴƴĩŶƿŶƄţƪƯřƺƗƱŚƯŹŵƹƾƿŚſŚƴƃƪƿŶƘţ
ƱŚƯŹŵƹŢǀƫŚƘƟ ŢſřƾƿƹŹřŵ )ë( ƾŞƬƣƲƿĦƳōŹŵƱŚƯŹŵƾƄŴŝźŧř
ƱĦǀƀĩřƶŝŻŚǀƳƂƷŚĩƹŜƬƣƶŝƾƳŚſŹƱĦǀƀĩřƂƿřżƟřźŝƪưŤƄƯ
źŧřƲƿřƶĩŢſřſƹƶŝǀƶƬ ƳǀšřźŤ ŚƷ  ŚºƷźĩƺƬŝƮǀƀƬĩƹŚƷźĩƺƬŝŚŤŝ
ťŵŚůƯƾ ŵƺƃ )ì( .ƳǀšřźŤ ŚƷ     ŦºƗŚŝƝŚºƇšǈºƌƗƱŵźĩƪƃŚŝ
ƹƵŶƃơƹźƗƱŶƃŵŚƄĭƶŝźŬƴƯ    ŢºƟŚŝƶºŝƾƳŚºſŹƱƺųƂƿřżƟř 
ŜƬƣƯƾ ŵŵźĭ )í( .    ƶºĩŵŹřŵƲºƿřƶºŝƵŹŚƃřƾƬƳŚŤſřƶƘƫŚƐƯƶģźĭ
     ƽŹŶºƇƲƿĦºƳōƱŚºƯŹŵŹŵšřźºŤǀƳŚºŝźĩƺƬŝŚºŤŝƱŚºƯżưƷƝźºƈƯ
ŜſŚƴƯ źţ Ţſř)î( .ŜƬƣƱŚŝźƋƂƿřżƟřŹŚƸƯŚŝŚƷźĩƺƬŝŚŤŝ  ŹŚºƄƟ
ƾƳŚƿźƃ      ĨºƿĥźƳŹŵōŢºǀƫŚƘƟŻřƾºƃŚƳŵŹŚºĩƺǀƯƾºƋŚŞƤƳřšŹŶƣƹ
ƮĩřŹƱĦǀƀĩřƶŝŵŹŚĩƺǀƯƽŚƋŚƤţƯƾ Ŷƴĩ )ç( .ŚƷƹŹřŵƲƿřƶƬưūŻř
Ưƾ Ʊřƺţ ƩƺƫƺƴţōƶŝŵźĩƵŹŚƃřƩřŹƺŤƯƹƩƺƫƺƳřźěƹźě )æå( .ƶƘƫŚƐƯ 
ŽƹŵŹŶƳƹÎ ƱŚƯŹŵŹŵřŹƲǀĜƿŶǀƠǀƳƹƩƺƬƿŵƹŹŚĩŵźŝŹŚĩƱřŹŚĪưƷƹ
ŶƳŵźĩƶƀƿŚƤƯŹřŶƿŚěƲƿĦƳō      ƹŹřŵƹŵźºƷŵƺºŝƱōźĮƳŚºǀŝŪƿŚºŤƳƶĩ
ŵŹŵšǈưůƂƷŚĩŹŵƱŚƀĪƿƾƄŴŝźŧřƽřŹřŵŵŹŵƱƹŶŝŢǀƫŚƘƟ
   ƩƺƬƿŵƹŹŚºĩƽƹŹřŵƾŞƳŚºūƉŹřƺƗŚƯřƶŤƃřŵƾŞƬƣŢůřźŤſřƱŚƯŻ
    ƲǀĜƿŶºǀƠǀƳƶºŝŢŞºƀƳ  ŢºſřźºŤưĩ )ææ( .  ƶºƘƫŚƐƯĤºſřǀšŶÏ ƹ
ƶƘƫŚƐƯĨƿƶĩƱřŹŚĪưƷƷŚĮƳŚƯŹŵƩŚƿřźţƩŚ    ŵƺºŝŹƺºĩƺºſƹŵ .  źºŧř
      ƽŹŶºƇƲƿĦºƳřƱřŹŚºưǀŝŹŵƪºǀƯŚěřŹƹƹƩřŹŶºƴƿřƽƹŹřŵƹŵƾƄŴŝ
źƣƾſŹźŝŵŹƺƯŹřŶƿŚěŵřŵŹř .   ŹŵƪºǀƯŚěřŹƹƶºĩŵƺºŝƱřźĮƳŚǀŝŪƿŚŤƳ 
ƮŗǈƗƩźŤƴĩ ŵŹŵ      źºŧřƩřŹŶºƴƿřƶºŝŢŞºƀƳƁŻŹƹƪưŰţŵƺŞƸŝƹ
ƱŚƯŹŵƩƹřƎųřŹźĩƺƬŝƮǀƀƬĩƽŚƷƹŹřŵźĮƄƷƹĦěƹƶŤƃřŵƽźŤƸŝ
ŵźĩƾƟźƘƯƽŹŶƇƲƿĦƳōƱřŹŚưǀŝ)æç( .ƾƄŴŝźŧřŵƺŞƸŝ  ƂƷŚºĩ
                                               
1 vanderdose 
2 Scheidt 
ŵŹŵšŶƯƩƺƏƹŵŹŵšǈưů ƾŞƬƣƱřŹŚưǀŝŹŵŧŐºţǀź   Źŵƾƿřżºƀŝ
ŵŹřŵźƔƳŵŹƺƯƽŹŚưǀŝŚŝŹŚưǀŝƽŹŚĭƽŻŚſƹƾĭŶƳŻŢǀƠǀĩŚƤţŹř
        ƱƺºģƾºŤŞƣřźƯƮǀºţƽřźºŝƮºƷƹƱŚĪºƃżěƽřźºŝƮƷźƯřƲƿřƶĩ
ºſřŹřŵŹƺųźŝƾƿǇŚŝŢǀưƷřŻřƱřŹŚŤſźě) Ţæè( .   ƮºƿĥŹŻřƽƹźºǀě
ƽƺƣŪƿŚŤƳŻřƲƯżƯƱřŹŚưǀŝŹŵƱōŻřŢƘŝŚŤƯƹƾƿƹŹřŵƁŻƺƯō ŚƷƽ 
ƱřŹŚŤſźě Ţſř. ƹŹřŵźŤƸŝƾƄŴŝźŧřŚƯřƅƺƈųƶŝ ŹŵŵŹŵƶƴǀƯŻŹŵ
ƲƿřƾŞƬƣƱřŹŚưǀŝƁŻƺºƯō ŚºƷ      ƽřźºŝřŹƾƳŚºƯŹŵƮºƿĥŹŻřƽƹźºǀěƹ
źĩŶƷřƺųŢƿƺƤţƱřŹŚưǀŝ) ŵæé( .ƶĩƵŵƺŝƱřźĮƳŚǀŝƽźŤƿƹƶƘƫŚƐƯ
ƵŶƃżƿƺŬţƱŚƳřƽřźŝƽźŤưĩƽŚƷƹŹřŵŵřŶƘţƶĩƾƴƯżƯƱřŹŚưǀŝŹŵ
Śƿƹ ƮƿĥŹæ Śƿç ƾƿƹŹřŵ ěƶŤƃřŵƹźŤƸŝƾƳŚƯŹŵƮƿĥŹŻřŹŚưǀŝƽƹźǀ
) ŢſřƶŤƃřŵŹŚưǀŝƽřźŝƽźŤƸŝƾƳŚƯŹŵŵźĪƬưƗæê( ƮƿĥŹƾƟźƏŻř 
ƮǀţƹƱřŹŚưǀŝƽřźŝƽŶūšŹƹźƋĨƿŵƹŶŰƯƽƹŹřŵƹƾƿƹŹřŵĨţ
ŢſřŢƯǈſ .    ŶºƘŝŹŵƱřŹŚŤºſźěƹƱŚºƯŹŵŶƘŝŹŵƱŚĪƃżěƵŻƹźƯř
ƾºƿƹŹřŵŶƴģƮƿĥŹŻřŹƺƟƹƶŝŢŞƣřźƯ    ºſřƾºŞƬƣƱřŹŚºưǀŝŹŵƵŵŚƠŤ
Ưƾ ŶƴƴĩřŸƫſŹźŝƾ ŚƷƽ ƮŤƀǀſŹŵƾƿƹŹřŵĨţƾƄŴŝźŧřƾƴǀƫŚŝ
ƱŚƯŹŵ ŢſřƽŶūšŹƹźƋĨƿƱřźƿřƾƿƹŹřŵĬƴƷźƟƹ .  ŹƺºƔƴƯƶŝ
ƲƿřƶŝŲſŚěƩřŒſ ƾƿƹŹřŵƮƿĥŹŢƿŵƹŶŰƯŢƸūŹŵ ƶƘƫŚƐƯ řƽ   Śºŝ
  ƾºƄŴŝźŧřƶºƀƿŚƤƯƝŶƷ      ŵřŶºƘţźºŝƭŻŚºǀŤƬƿŵƹƩƺºƳřźěƹźěƽƹŹřŵ
ŵŹŵšǈưůŹŵŵŹŵƵŹƹŵƩƺƏ ƶºŝǈŤŞƯƱřŹŚưǀŝ   ƽŹŶºƇƲƿĦºƳō 





     ŢºƟŚƿŹŵƱƹŶºŝƹƶƴǀºſŵŹŵŚºŝŹŚºŝƲǀƫƹřƽřźŝƶĩƽŹŶƇƲƿĦƳō 
ƷǀĢ ƶƳƺĭ ŹŵŜƬƣƆƈŴŤƯĨƃżěƶŝƾŞƬƣƽƹŹřŵƵŚĮƳŚƯŹŵ   ŜºƬƣ
   ƁƹŹƶºŝƵŵƺºưƳƶƘūřźƯŵźĩźƸƃƾĪƃżěƭƺƬƗƵŚĮƄƳřŵƶŝƶŤƀŝřƹ
ƱŚſō ŶƳŶƃśŚŴŤƳř .ŹřźƣƁŻŹƹŢƀţŢŰţřŶŤŝřžĜſŶƴŤƟźĭ Śŝ
řŵŚƳŚĩŜƬƣƲưŬƳřƶƯŚƴƄſźěƪǀưĪţ ƾƴƿĦƳōƵƹźĭŚƿŽǈĩƱō ŚºƷ 
ƁƹŹƶŝƹƆŴƄƯ śƹƞƫřƹŵŹŵƵŵŚſƾƟŵŚƈţ ŶƳŶƃƮǀƀƤţ .Śŝ
ƵŵŚƠŤººſřƶƯŚƴººƄſźěŻř    ĨººƿĥƺƫƺƿżǀƟƽŚººƷźǀƜŤƯŢººŞŧƶººĭźŝƹ
ĨǀƟřźĭƺƯŵšŚƈŴƄƯƾƟźƈƯƽƹŹřŵƕƺƳƹšŶƃŵřŶƘţ šǈưů
ƾŞƬƣŵŹŵ ƹ ŶƿŵźĭŢŞŧƱřŹŚưǀŝƁŻŹƹŢƀţƶŬǀŤƳ .ƱŚƯŹŵ Ǝſƺţ
źƷƶƳřŻƹŹŪƫŚƘƯĨƃżěŢƄƷ ŚŝŢƗŚſçå ƾƬǀƯ ƭźĭ   ƩƺºƫƺƳřźěƹźě
ƞƫřƵƹźĭƽřźŝ ƹèå ƾƬǀƯ ƭźĭ śƵƹźĭƽřźŝƭŻŚǀŤƬƿŵ   šŶºƯƶºŝ ë 
ƶŤƠƷ Ŷƃƕƹźƃ .ƶŝƱřŹŚưǀŝƶŤƠƷƹŵźƷƵŚĮƳŚƯŹŵ    ƶºƘūřźƯƶºƏƺŝźƯ
      ŵŹŵšǈºưůŵřŶºƘţƹšŶºƃźºƔƳŻřƢºƤŰƯƎºſƺţřŶŤŝřƵŵƺưƳ
ƿƹŹřŵƾŞƳŚūƉŹřƺƗƾ ƶƴƿŚƘƯŪƫŚƘƯĨƃżěƎſƺţžĜſƹƾſŹźŝ
Ưƾ ŶƳŶƃ .ƱŚƯŹŵƵŹƹŵƭŚưţřŹŵƂƃ ŤƠƷ) ƶƭŚưţľřŵŶŬƯ ưǀŝƹŵƱřŹŚ
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    ƾºŞƬƣƽŚºƷƹŹřŵźƿŚºſŚºŝƱŚƯŹŵƶƘƫŚƐƯŻřũƹźų   ƉŹřƺºƗŵƺºūƹ
ƾƿƹŹřŵŢŝŚƿŵƶŝǈŤŝř     ƵŵƺºŝƱŚŤºſŹŚưǀŝŹŵƽźŤºƀŝƹƹŹřŵƖºƐƣ
Ţſř .šŚƗǈƏřƽŹƹřŵźĭŹřżŝř    ƶºĭźŝƹƶƯŚƴºƄſźěƂƷƹĦºěƲƿřŹŵ
ƾƿřƹŹŚŝƍŚŞţŹřŹŵƶĩƵŵƺŝĨƿĥƺƫƺƿżǀƟƽŚƷźǀƜŤƯŢŞŧ ƶƯŚƴƄſźě
Żř      šǇŚºƤƯƹśŚºŤĩƶºƘƫŚƐƯŻřŶºƘŝƶĩƵŶƃƵŵŚƠŤſřřƺŤŰƯŹŚŞŤƗř
ŻřƶƯŚƴƄſźěƶǀƸţƹƎŞţźƯæå ƽŚƌƗřźƠƳƷǀŢŘ ŚŝƎŞţźƯƾưƬƗ
       ƵŶºƃŭźºƐƯšřźºƔƳƩŚºưƗřŻřŶºƘŝƶºĩƵŶƃƾƷřƺųźƔƳƕƺƋƺƯ
ŢſřƵŶƃƵŵŚƯōšŚƗǈƏřƽŹƹōƖưūŢƸūƶƯŚƴƄſźě .  ŢºƸūŚƯř
ƾƿŚƿŚěƁƹŹŻřƪǀưĪţ ƵŵŚƠŤſřƱŚƯżưƷ ƾĮŤƀŞưƷŜƿźƋƶƧƵŶƃ
ŻřƂǀŝƵŶƃƶŞſŚŰƯîæ/å ŢſřƵŵƺŝ .Ƶŵřŵ ŚƷ     ƭźºƳŻřƵŵŚƠŤºſřŚºŝ
ŹřżƟřSPSS  ƹŢƀţ ŚƷƽ ƪǀƬŰţƹƶƿżŬţƾƬǀƬŰţƹƾƠǀƇƺţƽŹŚƯō
ƿŵźĭŶ  
  
ƿƶŤƟŚ ŚƷ  
ŻřƕƺºưŬƯ ëå    ƹƩƺºƳřźěřźěƵƹźºĭƹŵŹŵŹřŶºƿŚěƲƿĦºƳōŹŚºưǀŝ
ƭŻŚǀŤƬƿŵè/ëí ŶƇŹŵ ƹŵźƯì/èæ ŶƇŹŵ ŶƳŵƺŝƱŻ .ƱřƹřźºƟ źºţƿƲ 
ŚŝƞǀƠųŵŹŵƾƴƿĦƳōŵŹŵŢǀƠǀĩêå ŶƇŹŵ ƾƴƿĦƳōŵŹŵƲƿźŤưĩƹ 
ŚŝƵŵŻŢƄůƹŵŹŵæåŶƇŹŵ Ƶŵƺŝ Ţſř .ƱřƹřźƟ źţƿƲ ƾƴƿĦƳōƶƤŞƏ Śŝ
íåŶƇŹŵ ƶƤŞƏƶŝƍƺŝźƯç ƲƿźŤưĩƹ    ƶºƤŞƏƶºŝƍƺŝźƯƱōè   Śºŝ
è/í ŶƇŹŵ ſřƵŵƺŝ) Ţ  ƵŹŚưºƃƩƹŶūæ(.     ƹźºƄǀƟƢºǀƣŵƱƺºƯŻō
ƱōźĮƳŚǀŝƹŵƾųƱƺƯŻō ŢƀţƶŬǀŤƳƹƲƿĦƳřŽǈĩźƔƳŻřƶĩƵŵƺŝ
   ƝǈŤºųřƩƺºƫƺƳřźěƹźěƹƭŻŚǀŤƬƿŵƵƹźĭƹŵƲǀŝƁŻŹƹƾºƴƘƯ Źřŵƽ
) ƵŵƺŝŭźƐƯåê/åP<šƹŚƠţŵŹŵŢǀƠǀĩźƔƳŻřƾƫƹ (ƾºƴƘƯ Źřŵƽ
ƶŤƃřŶƳ ŶƳř )åê/åP>( .ŚŝũƹŻƾţƱƺƯŻōåê/åp< ƶĩŵƺŝƱōźĮƳŚǀŝ
     ƵŹƹŵƩƺºƏźºŝƱŚºƯŹŵŻřƪºŞƣŚŝƶƀƿŚƤƯŹŵƩƺƳřźěƹźěŧŐºţŵŹŵǀź 
ƶŝƶŤƃřŵŹƺƏƽ ƶĩ řƿƲ ŧŐţǀź    šǈºưůŵřŶºƘţźŝƭŻŚǀŤƬƿŵƵƹźĭŹŵ
ŢºſřƵŵƺŝŵŹŵƵŹƹŵƩƺƏƹŵŹŵ )   ƵŹŚưºƃƩƹŶºūç( .   ƾºţƱƺºƯŻō
ŚŝƪƤŤƀƯåê/åp< ƠţźĮƳŚǀŝšƹŚƾƴƘƯ Źřŵ    ƾºƄŴŝźºŧřƲǀŝƽŹŚƯō
    ŵŹŵšǈºưůŵřŶºƘţźºŝƭŻŚǀŤƬƿŵƹƩƺƫƺƳřźěƹźěƵƹźĭƹŵŹŵƱŚƯŹŵ
ƶŝƵŵƺŝŹƺƏƽ ƶºĩ        źºŧřŵŹŵšǈºưůŵřŶºƘţƂƷŚºĩźºŝƭŻŚºǀŤƬƿŵ
ƂŴŝ źţ ŢſřƵŵƺŝ )ƵŹŚưƃƩƹŶūè( .  
  
) ƵŹŚưƃƩƹŶūæ:( ƾſŹźŝ ƾƴƿĦƳōƶƤŞƏƾƳřƹřźƟƶƀƿŚƤƯŢǀƠǀĩ ŚŝƱŚƯŹŵŢŰţƵƹźĭƹŵŹŵƁŻŹƹŢƀţƶŬǀŤƳƹƲƿĦƳōŵŹŵ ƩƺƳřźěƹźě ƭŻŚǀŤƬƿŵƹ 
ŵźĩźƸƃƾĪƃżěƭƺƬƗƵŚĮƄƳřŵƶŝƶŤƀŝřƹƾƳŚƯŹŵżĩřźƯƶŝƵŶƴƴĩƶƘūřźƯƲƿĦƳōƶŝǈŤŞƯƱřŹŚưǀŝŹŵ  
ŚƷźǀƜŤƯ  ƩƺƫƺƳřźěƹźěƵƹźĭ  ƮƿŻŚǀŤƬƿŵƵƹźĭ  ƽŹŚƯōŢƀţ  
ƲƿĦƳōŽǈĩ      
  
åê/åP< Ĩƿ  ì/çë%  è/íè% 
ƹŵ  è/ìè%  ì/æë%  
ŵŹŵŢǀƠǀĩ  ëå  ìå  
åê/åP>  
ƞǀƠų  ëå%  ìå%  
ƵŶƴƴĩŢůřŹŚƳ  éå%  è/çè%  
śźƐƌƯ    ì/ë%  
ƁŻŹƹŢƀţ      źƄǀƟƢǀƣŵƱƺƯŻō  
ŢŞŨƯ  ë/ëë%  çå%  
åê/åP<  
ƾƠƴƯ  é/èè%  íå%  
  
ŚŝźƄǀƟƢǀƣŵƱƺƯŻōåê/åp< ƝǈŤųřźĮƳŚǀŝƾƴƘƯ Źřŵ ƽŹŚƯō
ƵƹźĭƹŵŹŵƁŻŹƹŢƀţƱŶƃƾƠƴƯƲǀŝ ŚŝƱŚƯŹŵŢŰţ ƹƩřŹŶƴƿř
 ƱřŹŚưǀŝ ƭŻŚǀŤƬƿŵ Ƶƹźĭ Źŵ ƶĩ ƽŹƺƏ ƶŝ Ƶŵƺŝ ƭŻŚǀŤƬƿŵŹƺƏ ƶŝ 
ƾƴƘƯ Źřŵƽ  ƁŻŹƹ ŢƀţƱō ŚƷ źĮƳŚǀŝ ƶŬǀŤƳ Ʋƿř ƶĩ ƵŶƃ ƾƠƴƯ
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ƩƺƫƺƳřźěƹźěƵƹźĭ  ƭŻŚǀŤƬƿŵƵƹźĭ  
ƱŚƯŹŵŻřƪŞƣ  ƱŚƯŹŵŻřŶƘŝ  ƱŚƯŹŵŻřƪŞƣ  ƱŚƯŹŵŻřŶƘŝ  
ŵŹŵšǈưůŵřŶƘţ  ëî/å±ç  ìæ/å±åè/ç íç/å±îè/æ  êì/å±éë/æ  
  åê/åP>  åê/åP< 
ŵŹŵƵŹƹŵƩƺƏ  éî/å±èë/ç ê/å±éë/æ éè/å±ç/ç éì/å±è/æ  
ũƹŻƾţƱƺƯŻō  ååå/åP<  ååå/åP<  
  
ŚŝũƹŻƾţƱƺƯŻō åê/åP< ŵŹŵƵŹƹŵƩƺƏźŝƱŚƯŹŵŻřƪŞƣŚŝƶƀƿŚƤƯŹŵƩƺƳřźěƹźěƶĩƵŵƺŝƱōźĮƳŚǀŝ ƹŵŹŵšǈưůŵřŶƘţźŝƭŻŚǀŤƬƿŵƾƫƹ 
ƩƺƏƵŹƹŵ ŢſřƵŵƺŝźŧƺƯŹřŶƿŚěƲƿĦƳōƱřŹŚưǀŝŵŹŵ . 
  






ƩƺƫƺƳřźěƹźěƵƹźĭ  ƭŻŚǀŤƬƿŵƵƹźĭ  
ŵŹŵšǈưůŵřŶƘţ  ìæ/å±ç êì/å±éë/æ ååæ/åP<  
ƩƺƏŵŹŵƵŹƹŵ  ê/å±éë/æ éì/å±èè/æ åê/å p>  
  
       ƾºƄŴŝźºŧřźºƔƳŻřƶºĩƵŵƺºŝƱřźĮƳŚºǀŝƪƤŤºƀƯƾţƱƺƯŻō 
ƭŻŚǀŤƬƿŵƹƩƺƫƺƳřźěƹźě ƵŵƺŝƽŹŚƯōƝǈŤųřŵŹŵšǈưůŵřŶƘţƲǀŝ
ƶŝŹƺƏƽ ƶĩ ƱŵźĩƮĩŹŵƭŻŚǀŤƬƿŵźŧřŵřŶƘţ ƂŴŝźŧřŵŹŵšǈưů
ŢſřƵŵƺŞƳŵƺūƺƯƽŹŚƯōšƹŚƠţŵŹŵƵŹƹŵƩƺƏźŝƾƫƹƵŵƺŝźţ źŧř
ŢſřƵŵƺŝƱŚƀĪƿƹŹřŵƹŵƾƄŴŝ .  
   
ƶŬǀŤƳƹŦŰŝ ƽźǀĭ  
ŦŰŝ :ƂƷŚĩŦƗŚŝƩƺƫƺƳřźěƹźěƝźƈƯƶĩŵƺŝƱōźĮƳŚǀŝŪƿŚŤƳ
ƲƿĦƳōƶŝǈŤŞƯƱřŹŚưǀŝŹŵŵŹŵƵŹƹŵƩƺƏ ƵŶƃŹřŶƿŚě ŵřŶƘţŹŵŚƯř
ŵŹŵšǈưůƾƴƿĦƳōŧŐţǀź ƶŤƃřŶƳ .ƭŻŚǀŤƬƿŵƾƫƹƵƹǈƗ   źºŝƶĪƴƿřźŝ
ŵŹŵƵŹƹŵƩƺƏƂƷŚĩ   żºǀƳŵŹŵšǈưůŵřŶƘţźŝƵŵƺŝźŧƺƯŧŐºţǀź 
ŢſřƶŤƃřŵ .ƭŻŚǀŤƬƿŵƾƄŴŝźŧřƶĩƵŵƺŝƱōźĮƳŚǀŝŪƿŚŤƳƲǀƴĤưƷ
ŝƩƺƳřźěƹźěƶŝŢŞƀƳź  ŹřŶºƿŚěƲƿĦƳřƱřŹŚưǀŝŹŵŵŹŵšǈưůŵřŶƘţ
źţźŧŒƯ ŢſřƵŵƺŝ .šŚƘƫŚƐƯ    ƹƺºƀưƷƶºƘƫŚƐƯƲºƿřŪƿŚŤƳŚŝƽŵŚƿŻ
ŢſřƵŵƺŝƊƣŚƴŤƯ .ƶƘƫŚƐƯŹŵĤſřǀšŶÎ ƱřƺƴƗŚŝ    ƹŵƾºƄŴŝźºŧř
ŹřŶƿŚěƽŹŶƇƲƿĦƳřƱřŹŚưǀŝŹŵƪǀƯŚěřŹƹƹƩřŹŶƴƿřƽƹŹřŵ   Ĩºƿƶĩ
ŢſřƵŵƺŝŹƺĩƺſƹŵƶƘƫŚƐƯ .ŹŵƪǀƯŚěřŹƹ ƮºŗǈƗƩźŤƴĩ  ƂƷŚºĩ
ŵŹŵ   řŵƽźºŤƸŝźºŧřƩřŹŶƴƿřƶŝŢŞƀƳƁŻŹƹƪưŰţŵƺŞƸŝƹ  ƹƶŤºƃ
                                               
1 Scheidt 
ƱŚƯŹŵƩƹřƎųřŹźĩƺƬŝƮǀƀƬĩƽŚƷƹŹřŵźĮƄƷƹĦě ƱřŹŚưǀŝ   ƲƿĦºƳō
ƽŹŶƇ ŚŝƶĩƵŵƺưƳƾƟźƘƯ   źºƔƳŵŹƺºƯƶƘƫŚƐƯƶŬǀŤƳ    ŵƺºŝƺºƀưƷ
)æç( .ƶƘƫŚƐƯśřźŤºƀĭřÏ     ƶºƀƿŚƤƯƱřƺºƴƗŚºŝŧŐºţǀź   ƹƲǀĜƿŶºǀƠǀƳ
ƽŹŶƇƲƿĦƳřŹŚģŵƱřŹŚưǀŝŹŵƩƺƫƹźěƺŤƯŚěƿŹřŶ ƶĩ ƽřŹřŵƩƹřƵƹźĭ
   ƱōźĮƳŚºǀŝŪƿŚºŤƳƵŵƺŝƾŞƳŚūơƹźƗŶƣŚƟƭƹŵƵƹźĭƹƾŞƳŚūơƹźƗ
źĩƺƬŝƮǀƀƬĩƵƹźĭƶĩƵŵƺŝƵƹǈƗ   ƾưĪºƀƿřšǈºưůƂƷŚĩźŝ Źŵ
  ƂƷŚºĩƹŵŹŵƪưŰţŵƺŞƸŝƵŹƹŵ ŚºƷƽ     ŚºƷźĩƺƬŝŚŤŝƶºŝŢŞºƀƳŵŹŵ
źţźŧŒƯ ) Ƶŵƺŝæë( .ƵŹŚưƃƩƹŶūŪƿŚŤƳƶŝƶūƺţŚŝç ŢŞƀƳƭŻŚǀŤƬƿŵ
ƶŝƂŴŝźŧřƾƴƿĦƳřŵŹŵšǈưůŵřŶƘţƱŵźĩƮĩŹŵƩƺƫƺƳřźěƹźě   źºţ





ŽƹŵŹŶƳƹÑ      ƱŚºƯŹŵŹŵřŹƲǀĜƿŶºǀƠǀƳƹƩƺƬƿŵƹŹŚºĩƶºĩƱřŹŚĪưƷƹ
     ƹŹřŵƹŵźºƷƶºĩŵƺºŝƱřźĮƳŚºǀŝŪƿŚºŤƳŶƳŵźĩƶƀƿŚƤƯŹřŶƿŚěƲƿĦƳō 
ŵŹŵšǈưůƂƷŚĩŹŵƱŚƀĪƿƾƄŴŝźŧřƽřŹřŵŢǀƫŚƘƟŵŹŵƱƹŶŝ
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ƾŞƬƣŢůřźŤſřƱŚƯŻ    ƩƺƬƿŵƹŹŚºĩƽƹŹřŵƾŞƳŚºūƉŹřƺƗŚƯřƶŤƃřŵ
ƲǀĜƿŶǀƠǀƳƶŝŢŞƀƳŵƺŝźŤưĩ )ææ( .ƶƘƫŚƐƯěŚƃǀƹź ƵŵƺŝƱřźĮƳŚǀŝ
Ʃƺƫƺƴţō ƶŝŢŞƀƳ      ƹƾºƴƿĦƳōŵŹŵšǈºưůƂƷŚºĩŹŵƲǀĜƿŶºǀƠǀƳ





źŝ šǈưůŵřŶƘţ ŵŹŵƱřŹŚưǀŝ ŧŐţǀź ƶŝƶŤƃřŵŹƺƏƽ ƶĩ ƾƄŴŝźŧř
ŹŵƭŻŚǀŤƬƿŵ ŵŹŵšǈưůŵřŶƘţ ƩƺƫƺƳřźěƹźěƶŝŢŞƀƳ źţźŧŒƯ   Ƶŵƺºŝ
Ţſř .    ŚºƷźĩƺƬŝƮǀºƀƬĩƹŚºƷźĩƺƬŝŚºŤŝƱŚƯżưƷƱŚƯŹŵ   ŹŚºŧōƽřŹřŵ
ƷŚĮƳŚƯŹŵƾŜſŚƴƯ źţ   řŹŵŹŚºĩƺǀƯƱĦǀƀĩřƝźƈƯŚƷźĩƺƬŝŚŤŝŢſř
řŵƞǀƘƋŹƺţǈƿŵƹŻřƹźŧřƉƺƗŹŵƵŵřŵƂƷŚĩ   ƱŚºƯŹŵŹŵřŸºƫŶƳŹ
ŢƀǀƳŜſŚƴƯĨǀţŚưſŚĜſřƹŻřƹƲƿĦƳō .)çå( .ŚƷźĩƺƬŝƮǀƀƬĩ   ƶºŝ
      ƮºſŚĜſřƹơƹźºƗƾƳŚºƸĭŚƳƮºſŚĜſřƱŵźºĩħƺƬŝŹŵƾƿŚƳřƺţŢƬƗ
   ŢůřźŤºſřŢºƫŚůŹŵƲƿĦºƳōƭŹŶƴºſŹŵŚºƷƹŹřŵŻřƾºƃŚƳƾºƣƹźƗ
ŜſŚƴƯ źţ Ţſř )çæ( .ŹƺĩƺſƹŵƹƾƴǀƫŚŝƾƿŚƯŻōŹŚĩƶƘƫŚƐƯĨƿŹŵ
ƹŹřŵƹŵƾƄŴŝźŧřŹŵŢůřźŤſřŢƫŚůŹŵƩƺƫƺƳřźěƹźěƹƪǀƯŚěřŹƹƽ
ƽŹŶƇƲƿĦƳōƶŝǈŤŞƯƱřŹŚưǀŝ    ƪºǀƯŚěřŹƹƶºĩƵŵƺŝƱřźĮƳŚǀŝŪƿŚŤƳ




ƶĩŢſřƶƿźƔƳƲƿřźĮƳŚǀŝŵƺųƶĩ    ƲƿĦºƳřŵŚºŬƿřŹŵƮſŚĜſřƂƤƳ
ƽŹŶƇƶŤƀūźŝ źţ źƔƳƶŝƯƾ ŶſŹ .ƾƴǀƫŚŝƾƿŚƯŻōŹŚĩƶƘƫŚƐƯĨƿŹŵ
ŶƯƾƳǇƺƏƱŚƯŹŵŹƺĩƺſƹŵǈŤŞƯƱřŹŚưǀŝŹŵŚƷźĩƺƬŝƮǀƀƬĩŚŝš
ƱŵźĩƶƟŚƋřŹřŶƿŚěŚƳƲƿĦƳōƶŝƳǀšřźŤ ŚƷ ƲǀĜƿŶǀƠǀƳƶŝŚƷźĩƺƬŝŚŤŝƹ 
  ơƹźºƗŶºƳƺǀěƶŝŻŚǀƳŹŵƱřŹŚưǀŝƶūƺţƪŝŚƣƂƷŚĩƶŝźŬƴƯ   ƽřźºŝ
ƢǀƤŰţƲƿřƶģźĭƵŶƃŵŹŵƂƷŚĩŧŐţǀź   ŢºƿŹƂƷŚĩŹŵƾƳřŶƴģ
ŢºſřƶŤƃřŶƳƾƳŚƸĭŚƳīźƯƹŵŹŚĩƺǀƯŽƺŤĩŹŚƠƳř )çè(   ƾºƟźƏŻř
ƱŚƯżưƷƱŚƯŹŵƳǀšřźŤ ŚƷ ŢŞƀƳƽŹŶƇƲƿĦƳřŹŵŚƷźĩƺƬŝƮǀƀƬĩŚŝ
ŹƺţǈƿŵƹŻřƹźŧřŻřƾƃŚƳźƯřƲƿřŢſřźŧƺƯŹŚǀƀŝƾƿƹŹřŵĨţƱŚƯŹŵ
ƳǀšřźŤ ŢſŚƷ )çé( .   ŭźºƐƯšŚºƘƫŚƐƯŻřƽŹŚǀƀŝŪƿŚŤƳƶŝƶūƺţŚŝ
ŚƷźĩƺƬŝƮǀƀƬĩŚŝƲƿĦƳōƾŞǀĩźţƱŚƯŹŵƵŶƃ  ŚºƷźĩƺƬŝŚŤŝƹšřźŤǀƳ
ŹŚŧō ƾƳŚƯŹŵ ƶŤƃřŵƽźŤƸŝ ƾŞƳŚūƉŹřƺƗƹƾƿƹŹřŵƪųřŶţƱŚĪƯřŚƯř
ŭźƐƯŹŚưǀŝƽřźŝżǀƳƽźŤƄǀŝƯƾ Ŷƴĩ      źºŧřŢºƸūŹŵƶºƘƫŚƐƯřŸºƫ
    ŶºƘŝŹŵŢºǀưƷřŚºŝŹŚǀƀŝƲƯżƯƱřŹŚưǀŝƽřźŝƾƿƹŹřŵĨţƾƄŴŝ
ŢſřƾŤŞƣřźƯƹƾƳŚƯŹŵ .)çê( .ưƷǀƲ ŹƺƏ ƱřźĮƳŚǀŝƽźŤƿƹƶƘƫŚƐƯ
ƾƴƯżƯƱřŹŚưǀŝŹŵƶĩƵŵƺŝ    ƱŚºƳřƽřźºŝƽźŤưĩƽŚƷƹŹřŵŵřŶƘţƶĩ
ŚƿƹƵŶƃżƿƺŬţ ƮƿĥŹæ Śƿç ƾƿƹŹřŵ    ƮºƿĥŹŻřŹŚºưǀŝƽƹźǀěƶŤƃřŵ
      ŢºſřƶŤºƃřŵŹŚºưǀŝƽřźºŝƽźºŤƸŝƾƳŚƯŹŵŵźĪƬưƗƹźŤƸŝƾƳŚƯŹŵ
)æê(.   
ƽźǀĭƶŬǀŤƳ :ŵŹŵŢǀƠǀĩŹŵƮƿŻŚǀŤƬƿŵƾƄŴŝźŧřŵŹŵƂƷŚĩ
ŹřŶƿŚěƲƿĦƳōƶŝǈŤŞƯƱřŹŚưǀŝŵŹŵƵŹƹŵƩƺƏƹŒƯźţźŧ   ƶºģźĭƵŵƺŝ
ŶƴƯŻŚǀƳźŧřƲƿřŶǀŗŚţ    ƾƿŚºǀƟřźƜūŢºǀƘƣƺƯŹŵƢºǀƤŰţ   ƹšƹŚºƠŤƯ
ŢſřźŤƄǀŝƶƳƺưƳƮŬů . 
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Abstract 
Background & Aims: Ischemic heart disease is one of the most common, chronic and deadly diseases in 
the world. Ischemic heart disease treatment consists of ensuring the patient, its identification, 
eliminating risk factors, lifestyle changes and drug therapy. The study tries to compare the efficacy of 
propranolol and diltiazem on the intensity, duration and periods of pain in the angina patients referred 
to the heart clinic of Shahrekored University of Medical Sciences.  
Materials & Methods: In a cross sectional study 60 patients with stable angina were selected with 
convenience sampling. Initially after receiving exercise testing, and completing the questionnaire to 
determine angina class, the patients were randomly divided into A and B groups by using the 
questionnaire and related chart recording of physiological variables. 
Demographic characteristics, types of drugs, the number of angina attacks and the results of the stress 
test were registered. The patients were treated with 20 mg propranolol every 8 hours daily, and with 
30 mg diltiazem for 6 weeks, and they were considered as Group A, and Group B respectively. The 
patients were examined by a cardiologist for 6 weeks. Inclusion criteria to the survey were typical 
angina pain, positive exercise test, patient satisfaction, and dwelling in the provincial capital. 
Exclusion criteria were negative exercise test, treated with cardiac drugs, drug complications, 
diabetes, severe ischemic attacks, and cutting off medication. Hospitalization data were recorded by a 
questionnaire, and the collected papers were analyzed by using SPSS statistical software.  
Results: The results showed that from the 60 stable angina patients in both groups of A, and B, 68.3 
% were male, and 31.7 % were females. The most abundant minor pain, was angina pain, with 50% , 
and the least pain, was terrified angina pain with 10%.  The most abundant Angina class was class 2 
with  80%,  and  lowest  was  class  3  with  8.3%.  There  was  a  significant  differences  between  the  two  
groups of treatment concerning the drug’s effectiveness, number of attacks of pain, and the effect of 
pain. Fisher's exact test indicated that there was a significant difference between negative exercise test 
in the two groups.  
Conclusion: Although both Ayndral and diltiazem had an effective role on the quality of pain, 
number of attacks, period of pain in patients with stable angina, but this effect was more effective in 
diltiazem group. More investigations with bigger sample size are needed. 
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